PTC Therapeutics (NASDAQ:PTCT) Director Sells $916,200.00 in Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) Director Glenn Md Phd Steele, Jr. sold 12,000 shares of the company’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $76.35, for a total transaction of $916,200.00. Following the completion of the sale, the director directly owned 18,500 shares in the company, valued at approximately $1,412,475. This represents a 39.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

PTC Therapeutics Price Performance

Shares of PTC Therapeutics stock opened at $76.85 on Friday. The firm has a market cap of $6.17 billion, a PE ratio of 8.98 and a beta of 0.49. PTC Therapeutics, Inc. has a 1 year low of $35.95 and a 1 year high of $87.50. The stock has a fifty day moving average price of $76.43 and a 200-day moving average price of $62.53.

PTC Therapeutics (NASDAQ:PTCT) last released its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.20 EPS for the quarter, topping the consensus estimate of ($1.19) by $1.39. The company had revenue of $211.01 million during the quarter, compared to the consensus estimate of $177.42 million. PTC Therapeutics had a net margin of 42.25% and a negative return on equity of 194.11%. PTC Therapeutics’s revenue for the quarter was up 7.2% on a year-over-year basis. During the same period last year, the firm earned ($1.39) EPS. As a group, equities analysts anticipate that PTC Therapeutics, Inc. will post -4.52 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Smartleaf Asset Management LLC boosted its holdings in PTC Therapeutics by 101.3% in the third quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 236 shares in the last quarter. Optiver Holding B.V. boosted its holdings in PTC Therapeutics by 96.5% during the third quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 249 shares in the last quarter. Comerica Bank increased its position in shares of PTC Therapeutics by 868.5% in the third quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 469 shares in the last quarter. IFP Advisors Inc increased its stake in shares of PTC Therapeutics by 68.1% during the 3rd quarter. IFP Advisors Inc now owns 765 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 310 shares in the last quarter. Finally, PNC Financial Services Group Inc. increased its position in PTC Therapeutics by 42.1% during the 2nd quarter. PNC Financial Services Group Inc. now owns 995 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 295 shares in the last quarter.

Wall Street Analyst Weigh In

PTCT has been the subject of several research analyst reports. Wall Street Zen upgraded PTC Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, January 3rd. Weiss Ratings restated a “hold (c)” rating on shares of PTC Therapeutics in a research report on Monday, December 29th. Barclays upped their price target on shares of PTC Therapeutics from $46.00 to $68.00 and gave the stock an “equal weight” rating in a research report on Wednesday, November 5th. Citigroup upped their price target on shares of PTC Therapeutics from $50.00 to $75.00 and gave the company a “neutral” rating in a research note on Wednesday, November 5th. Finally, Morgan Stanley restated an “overweight” rating and issued a $90.00 price objective on shares of PTC Therapeutics in a research report on Thursday. Nine equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, PTC Therapeutics has a consensus rating of “Hold” and an average price target of $77.27.

PTC Therapeutics News Roundup

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Recent fundamentals still supportive — PTC reported an earnings and revenue beat in its last quarter (Nov.) and maintains strong margins relative to peers, which underpins the stock’s valuation and analyst interest. MarketBeat PTCT profile
• Neutral Sentiment: Small inducement grant: the company approved 300 restricted stock units for a new non‑executive employee on Jan. 2 — immaterial dilution and likely not a major near‑term driver. PR Newswire: Inducement Grants
• Neutral Sentiment: Analyst consensus is a “Hold” with a mixed set of price targets and ratings — this produces limited conviction among buy‑side actors and can temper short‑term moves. Analyst consensus report
• Negative Sentiment: Heavy insider selling disclosed in multiple Form 4s — several executives and directors (including the CEO, CFO, EVP, VPs and others) sold several tens of thousands of shares across Jan. 6–7 at ~\$77 per share, representing millions of dollars of proceeds. Collective insider sales at this scale can put near‑term downward pressure on the stock and signal to some investors that insiders are taking gains. The filings and aggregated alert are here for review. InsiderTrades: Jan. insider sales alert

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.